Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

The section presents a review of diastolic congestive heart failure, commonly called HFpEF. Reviews of systolic congestive HF, or HFrEF, valvular heart disease, pulmonary hypertension and right HF ...

Recent trials have shown the effectiveness of GLP-1 therapies in reducing cardiovascular risk and improving outcomes in patients with obesity and HFpEF. These therapies have the potential to ...

“HFpEF accounts for nearly half of all heart failure cases, and in the U.S. almost 60% of those impacted also live with obesity. Despite a continuing increase in the number of people with both ...

The company has also received FDA approval to initiate LEVEL-2, a global Phase 3 study for TNX-103 in PH-HFpEF, with the first patient expected to be enrolled later this year. This study aims to ...

The open-label study enrolled those with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (“PH-HFpEF”) and heart failure with reduced ejection fraction (“PH ...